PDCD1 and melanoma: For instance, the combination therapy of Nivolumab (a PD-1 inhibitor) and Ipilimumab (a CTLA-4 inhibitor) has demonstrated remarkable efficacy in multiple tumor types, including melanoma, colorectal cancer (CRC), and NSCLC [123–125].